HASBROUCK HEIGHTS, N.J., May 13, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2011, prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,431,091, or $0.14 per share for the quarter ending March 31, 2011, compared to $1,183,352, or $0.04 per share for same period in 2010. Net losses include stock-based compensation charges of $3,583,258 in 2011 and $109,022 in 2010. The increase in net losses is attributable to higher stock-based compensation charges compared to 2010. Revenues from sales ($110,615) and licensing ($654,400) totaled $765,015 for the first quarter of 2011, compared to revenues from sales of $246,861 for the same period in 2010. The weighted average number of common shares at March 31, 2011 was 32,578,523, compared to 31,473,825 at March 31, 2010.
